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Case Report
Primary Upper Urinary Tract Small Cell Carcinoma:
A Case Series and Literature Review
Patrick J. Hensley, MD, Amul A. Bhalodi, MD, and Shubham Gupta, MD
Abstract
Background: Primary upper urinary tract small cell carcinoma (SCC) is exceedingly rare with <30 cases reported
in the literature. Little is known about the incidence, diagnosis, treatment, and outcomes in these patients. We
present a series of three patients with primary upper tract SCC.
Case Presentation: Patient 1 is an 89-year-old Caucasian male who presented with hydroureteronephrosis and
a mass in the proximal right ureter. Biopsy revealed SCC. Without further intervention, the patient died
2 months after his diagnosis. Patient 2 is a 67-year-old Caucasian female who underwent left laparoscopic
nephroureterectomy for primary distal ureteral SCC, pT4N1M0. She developed lymphadenopathy and completed
external beam radiation to the pelvis and four courses of cisplatin-based chemotherapy. She died from metastatic
disease 7 months after diagnosis. Patient 3 is a 45-year-old female who underwent open right radical nephrectomy,
retroperitoneal lymph node dissection, and hepatic metastasectomy for metastatic primary upper tract SCC,
pT3N1M1. She underwent two subsequent retroperitoneal debulking procedures for recurrence followed by
treatment with octreotide. She developed widespread metastasis and was treated with temozolomide and ca-
pecitabine before her death 80 months after diagnosis.
Conclusion: This series contributes to the limited knowledge of the management and natural course of primary
upper tract SCC. Patient 1 represents the first disease-specific mortality reported in a patient who received no
therapy. Patient 3 represents the longest reported survival with metastatic disease, and the first treated with
octreotide. The patient was managed with aggressive repeat surgical resection and exhibited 2 years of
progression-free survival on octreotide. Emphasis should be placed on aggressive resection of all visible disease
combined with the use of multimodal adjuvant chemoradiation for selected patients in this rare disease.
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Introduction and Background
Primary small cell carcinoma (SCC) of the genito-urinary tract is a rare entity, comprising an estimated
0.7% of all bladder malignancies.1 Primary upper tract SCC
is exceedingly rare, with literature limited to < 30 case re-
ports.2–4 We report a series of three cases of primary SCC of
the upper urinary tract, with discussion of clinical presenta-
tion, therapeutic course, and long-term outcomes.
Case 1
An 89-year-old Caucasian male presented with right flank
pain and gross hematuria with clot retention. He had a remote
history of smoking pipe tobacco. Medical history included
coronary artery disease with coronary stents. His Eastern Co-
operative Oncology Group (ECOG) performance status was 2.
The patient had acute renal insufficiency with serum creatinine
of 2.03mg/dL (baseline <1mg/dL).
A noncontrasted CT of the abdomen and pelvis showed
moderate right hydroureteronephrosis secondary to a mass
in the proximal right ureter (Fig. 1A). The patient under-
went cystoscopy, bilateral retrograde pyelography, and
right ureteroscopy. A classic ‘‘Goblet Sign’’ was identified
on retrograde pyelography (Fig. 2A) and ureteroscopy
revealed a large, friable, endophytic mass obliterating the
lumen of the proximal ureter. Cold cup biopsies were obtained
through a semirigid ureteroscope and a ureteral stent was placed.
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Histologic evaluation revealed SCC characterized by positive
immunohistochemical staining for CAM 5.2 (Fig. 2B, C).
After consultation with medical oncology, the patient op-
ted for surveillance of the mass secondary to his age and
deconditioning. He was admitted to a hospice service and
died 2 months after diagnosis.
Case 2
A 67-year-old Caucasian female presented with gross hema-
turia and left flank pain. She denied history of tobacco use and
medical history included obesity, hypertension, hyperlipidemia,
anxiety, depression, and asthma. Her ECOG performance status
was 1. Imaging showed a distal left ureteral mass (Fig. 1B) and
small left renal mass. She underwent ureteroscopy that revealed
a pedunculated mass in the distal left ureter. The patient un-
derwent laparoscopic left nephroureterectomy. Pathology re-
vealed SCC of the distal left ureter with one para-aortic lymph
node positive for metastatic SCC and positive periureteral soft
tissue margins, pT4N1. She also had an incidental type I
papillary renal cell carcinoma, pT1a. Immunohistochemical
analysis of the ureteral tumor revealed positive staining for
synaptophysin, chromogranin, and pancytokeratin. The tumor
stained negative for CD45 and P63.
The patient subsequently developed pelvic lymphadenop-
athy on restaging imaging 5 weeks after nephroureterectomy.
She underwent four courses of cisplatin and etoposide fol-
lowed by consolidative external beam radiation to the pelvis.
She developed metastasis to the left adrenal gland as well as
recurrence in the pelvis. She developed acute respiratory
failure secondary to a malignant pleural effusion. The patient
was transferred to the hospice service and died 7 months after
her initial diagnosis.
Case 3
A 45-year-old Caucasian female presented with abdominal
pain. She was a current one pack-per-day smoker and medical
history included obesity, hypertension, and previous myocardial
FIG. 1. Axial noncontrast CT section from Case 1 de-
picting a proximal right ureteral mass (white arrow, A).
Coronal noncontrast CT section from Case 2 depicting a
distal left ureteral mass (white arrow, B). Axial section of
excretory phase-contrasted CT from Case 3 depicting a
large, heterogeneous, enhancing right renal mass (C).
FIG. 2. Retrograde pyelogram characterized by the classic
‘‘Goblet Sign’’ with filling defect (asterisks) indicative of
ureteral obstruction from Case 1 (A). Hematoxylin and eosin-
stained section revealing clusters of small palisading cells
with hyperchromatic nuclei and crushed artifact (600· , B).
Cam 5.2 staining specific for neuroendocrine differentiation
(600· , C).
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infarction. Her ECOG performance status was 1 at presentation.
Imaging showed a 9 cm right renalmass (Fig. 1C), multiple liver
lesions concerning for metastases, and a right adnexal mass. She
underwent percutaneous biopsy of a liver lesion that showed
metastatic neuroendocrine carcinoma. She underwent open
right radical nephrectomy, retroperitoneal lymph node dis-
section (RPLND), hepatic metastasectomy, total abdominal
hysterectomy, and bilateral salpingo-oophorectomy. Pathol-
ogy analysis revealed primary SCC of the right kidney with
liver metastases and positive interaortocaval (2/2 positive
nodes) and paracaval (2/2 positive nodes) lymph nodes. All
margins of resection were negative and the final pathologic
stage of the renal neuroendocrine tumor was pT3N1M1. The
tumor and metastases stained positive for synaptophysin and
CD56 but negative for chromogranin, CD10, CD7, and CD20.
She also had a FIGOgrade 1 serous tumor of the right ovary and
high-grade endometrial dysplasia. Her postoperative course
was complicated by a myocardial infarction and cardiac arrest
necessitating cardiopulmonary resuscitation.
The patient developed bulky retroperitoneal lymphade-
nopathy in her initial 3-month postoperative restaging im-
aging and underwent repeat RPLND. Pathology analysis
revealed metastatic SCC in 2/4 lymph nodes. She was sub-
sequently lost to follow-up and re-presented 16 months after
her initial diagnosis with further retroperitoneal adenopathy.
Repeat RPLND showedmetastatic SCC in 2/17 lymph nodes.
She was again lost to follow-up and returned 36 months
after initial diagnosis with supraclavicular and retroperito-
neal lymphadenopathy and hepatic and skeletal metastases.
She was managed with octreotide for 2 years. Imaging re-
vealed disease progression and she was transitioned to sal-
vage temozolomide and capecitabine, which she tolerated
for 3 months before being admitted with acute onset mul-
tisystem organ failure. She died 80 months after her initial
diagnosis.
Discussion and Literature Review
The true incidence of primary upper tract SCC is difficult
to define given its rarity and common pathologic misclassi-
fication. The genitourinary tract is the second-most common
extrapulmonary origin of SCC to the gastrointestinal tract.1
Endoscopically, SCC of the upper and lower urinary tract is
characterized by broad-based polypoid and endophytic masses
that are often indistinct from papillary urothelial lesions. Two
staging systems of extrapulmonary SCC exist: (1) Veterans
Administration Lung Study Group system described for pri-
mary lung tumors, which assigns patients into limited (tumor
confined to a single radiation therapy treatment field without
nodal metastases) or extensive disease categories and (2)
American Joint Committee on Cancer TNM system.3 Pro-
posed etiologies of neuroendocrine malignancies in the
urinary tract include neuroendocrine differentiation of ur-
othelial cells or pluripotent stem cells, presence of neuro-
endocrine cells within the urinary tract, or trapped neural
crest cells during embryology.3
SCC is histologically characterized by small, palisading
cells with a high nuclear:cytoplasm ratio and high mitotic
index. Immunohistochemical signatures common to these
tumors include positive staining for the neuroendocrine
markers CD56, synaptophysin, neuron-specific enolase,
and chromogrannin A as well as pancytokeratin and low
molecular weight cytokeratin (CAM 5.2). In a review of
histology from 10 patients initially diagnosed with pri-
mary upper tract SCC, three cases were reclassified as ei-
ther poorly differentiated squamous cell carcinoma or
urothelial carcinoma.1 SCC commonly coexists with other
primary malignancies, including urothelial carcinoma in
62% of cases.2 In addition, it is prudent to exclude meta-
static pulmonary SCC to the upper tract, which has been
reported.1
The median age of presentation of upper tract SCC is 66.5
years, with a male predominance (64%). In the largest meta-
analysis of upper tract SCC, 72% of patients presented with
either pT3 or pT4 disease. Although only 3% of cases re-
ported had detectable distant metastases at the time of diag-
nosis, 54% developed metastases at a median time of 13
months from diagnosis.2
Multimodal regimens have been implemented for the
treatment of upper tract SCC, including surgery, radiation,
and adjuvant chemotherapy with platinum-based regimens.
Median survival after diagnosis ranges from 8.2 to 23months.1–3
In the largest study of therapeutic outcomes in upper tract SCC,
median survival was higher in those patients who received
adjuvant chemotherapy, although this did not reach statistical
significance (24 months vs 12months; p=0.56).2 Radiographic
response to neoadjuvant cisplatin-based regimens as well as
irinotecan has also been reported.3,4
The mean age of our cohort at the time of diagnosis was
67 years. Two patients presented with node positive dis-
ease at the time of surgery. Notably, patient 3 underwent
extensive lymphadenectomy and hepatic metastasectomy
at her index operation followed by debulking of all visible
retoperitoneal disease on two occasions. She was then man-
aged with octreotide resulting in progression-free survival for
2 years before being switched to salvage temozolomide and
capecitabine. This is the first reported use of the somatostatin
analogue in the management of upper tract SCC. This patient
(pT3N1M1), managed with aggressive and repetitive sur-
gical resection and multimodal therapy, experienced an
80-month survival, the longest disease-specific survival in a
patient with metastatic upper tract SCC reported (previously
15 months in a patient with pT3N0M1 disease managed with
nephroureterectomy).2 Conversely, patient 1 represents the first
disease-specific mortality reported in a patient with upper tract
SCC who received no extirpative surgery or chemotherapy.
He died within 2 months of biopsy-proven diagnosis, empha-
sizing the aggressive natural course of this disease and further
reinforcing the role of extirpative surgery.
Conclusion
Primary ureteral SCC is an exceedingly rare malignancy
characterized by aggressive tumor behavior and therapeutic
resistance. Previous series have observed improved disease-
specific survival in patients managed with adjuvant chemo-
therapy relative to surgery alone. The current series highlights
the importance of combining classic radiographic and endo-
scopic findings with expert histopathologic evaluation to dis-
tinguish common urothelial lesions from SCC, which portends
a dramatically different therapeutic regimen and prognosis.
Our series emphasizes the combined role of aggressive re-
section of all visible disease, including lymphadenectomy,
metastasectomy, and resection of recurrent, localized disease,
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with multimodal adjuvant chemoradiation to improve onco-
logic outcomes in this rare disease entity.
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